MedTrace Logo

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

NCT02902601 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-04-27

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the safety and tolerability of JNJ 54175446 in participants with Major Depressive Disorder (MDD).

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

JNJ-54175446, 600 mg

Participants will receive JNJ-54175446, 600 mg as an oral suspension.

DRUG

JNJ-54175446, 150 mg

Participants will receive JNJ-54175446, 150 mg as an oral suspension.

OTHER

Placebo

Matching placebo to JNJ-54175446

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-17
Primary Completion
2017-06-02
Completion
2017-06-07

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02902601 on ClinicalTrials.gov